A Randomized, Double-Blind, Active-Control Study of Sertraline Versus Venlafaxine XR in Major Depressive Disorder
J Clin Psychiatry 2006;67:1674-1681
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Sertraline may produce dual
neurotransmitter effects similar to the
serotonin-norepinephrine reuptake inhibitors (SNRIs); however, it has
been tested against an SNRI in only 1 previous study,
and never at an optimal dose. The objective of the
current multisite study was to compare relatively higher
doses of sertraline (i.e., 150 mg/day) and venlafaxine
extended release (XR) (225 mg/day) in outpatients
with major depressive disorder.
Method: Subjects with DSM-IV major
depressive disorder were randomly assigned to 8 weeks of
double-blind treatment with sertraline (N = 82) or
venlafaxine XR (N = 78). The study ran from January 2002
through January 2003. The primary outcome measure was
the Quality of Life Enjoyment and Satisfaction
Questionnaire; secondary outcome variables included the
17-item Hamilton Rating Scale for Depression.
Results: Both treatments led to significant
improvement in depressive symptoms and
quality-of-life measures. No significant differences were noted
between treatment groups for final scores on the
primary or secondary measures. The treatment groups did
not differ significantly in the percentage of
responders (sertraline = 55%, venlafaxine XR = 65%; intent-to-treat [ITT] sample) or remitters (sertraline
= 38%, venlafaxine XR = 49%; ITT sample), although the proportions are similar to those found in
earlier selective serotonin reuptake inhibitor (SSRI) vs.
venlafaxine meta-analyses. In patients who achieved
the maximum dose of drug and maintained it for 3
weeks, response rates were similar to those found at
lower doses (sertraline = 59%, venlafaxine XR = 70%);
however, remission rates for this sample were
comparable for both drug groups (sertraline = 48%, venlafaxine
XR = 50%).
Conclusions: The efficacies of sertraline and
venlafaxine XR were comparable. Although response
and remission rates did not differ statistically, the
rates were analogous to those reported in previous
meta-analyses. However, at clinically relevant higher
doses, the remission rates were very similar.
Registration: ClinicalTrials.gov identifier NCT00179283.